High Risk References

#1

Agoston, P
Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients

Brachytherapy 2011;10(5):376-84

Find this article


#2

Arcangeli, S
(Conventional dose)Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer

IJROBP 2012;84(5):1172-78

Find this article


#3

Arcangeli, S
(Hypofractionation dose)Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer

IJROBP 2012;84(5):1172-78

Find this article


#4

Arcangeli, G
Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial.

J Clin Oncol 2017;epub Mar 29():

Find this article


#5

Arcangeli, G
Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial.

J Clin Oncol 2017;epub Mar 29():

Find this article


#6

Aoki, M
Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)

J Radiat Res. 2014;55(3):527-32

Find this article


#7

Aoun, F.
Predicitve factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.

Scand J Urol 2017;51(1):20-26

Find this article


#8

Bahn, D
Targeted Cryoablation of the Prostate: 7_Year Outcomes in the Primary Treatment of Prostate Cancer

Urology 2002;60(2A):3-11

Find this article


#9

Baker, CB
Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma

Prostate Cancer 2016;2016(Art. ID. 2674954):8 pgs

Find this article


#10

Baker, CB
Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma

Prostate Cancer 2016;2016(Art. ID. 2674954):8 pgs

Find this article


#11

Bece, A
High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity.

Brachytherapy 2015;14(5):670-76

Find this article


#12

Berglund, RK
Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Prostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109

Urology 2012;79(3):633-37

Find this article


#13

Bittner, N
Whole pelvis radiotherapy in combination with interstitial brahytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high risk prostate cancer

IJROBP 2009;76(4):1078-1084

Find this article


#14

Bittner, N
Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy

Brachytherapy 2012;11(4):250-55

Find this article


#15

Bittner, N
Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories.

Brachytherapy 2015;14(6):766-72

Find this article


#16

Bolla, M
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomized controlled trial (EORTC trial 22911).

Lancet 2012;380(9858):2018-27

Find this article


#17

Boorjian,S
Mayo Clinic Validation of the D'Amico Risk Group Classification for Predicting Survival…

J. Urology 2008;179():1354-1361

Find this article


#18

Bryant, C
Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-=escalated image-guided proton therapy for prostate cancer.

Urology 2015;95(1):422-34

Find this article


#19

Burri, R
Young men have equivalent biochemical outcomes compares with older men after treatment with brachytherapy for prostate cancer

IJROBP 2010;77(5):1315-21

Find this article


#20

Busch, J
Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience

BJU Int 2012;110(11):E985-90

Find this article


#21

Carver, B
Long-term outcome following radical prostatectomy in men w/clinical stage T-3 prostate cancer

J. Urology 2006;176():546-568

Find this article


#22

Ciezki, JP
A comparison between low-dose-rate brachytherapy with or without androgen deprivation, external beam radiation therapy with or without androgen deprivation, and radical prostatectomy with or without adjuvant or salvage radiation therapy for high-risk prostate cancer.

IJROBP 2017;97(5):962-75

Find this article


#23

Ciezki, JP
A comparison between low-dose-rate brachytherapy with or without androgen deprivation, external beam radiation therapy with or without androgen deprivation, and radical prostatectomy with or without adjuvant or salvage radiation therapy for high-risk prostate cancer.

IJROBP 2017;97(5):962-75

Find this article


#24

Ciezki, JP
A comparison between low-dose-rate brachytherapy with or without androgen deprivation, external beam radiation therapy with or without androgen deprivation, and radical prostatectomy with or without adjuvant or salvage radiation therapy for high-risk prostate cancer.

IJROBP 2017;97(5):962-75

Find this article


#25

Cohen, J
Ten-Year Biochemical Disease Control for patients with prostate cancer treated with cryosurgery as primary therapy

Urology 2008;71(3):516-518

Find this article


#26

Critz, F
10 Year disease free survival rates after simultaneous irradiation fro prostate cancer with a focus on calulation and methodology

J. Urology 2004;172():2232-2338

Find this article


#27

Critz, FA
25-year disease-free survival rate after irradiation for prostate cancer calculated with the prostat specific antigen definition of recurrences used for radical prostatectomy

J Urol 2013;189(3):878-83

Find this article


#28

Crouzet, S
Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncological outcomes and morbidity in 1002 patients

Eur Urol 2013;65(5):907-14

Find this article


#29

Dattoli, M
Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

Cancer 2007;110(3):551-555

Find this article


#30

Dattoli, M
Long-Term Outcomes for Patients with Prostate Cancer Having Intermediate and High-Risk Disease, Treated with Combination External Irradiation and Brachytherapy

Journal of Oncology 2010;2010():Article ID 471375 6pgs.

Find this article


#31

Dearnaley, D
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Lancet Oncol 2016;17(8):1047-60

Find this article


#32

Dearnaley, D
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RTO1 randomised controlled trial

Lancet 2007;8():475-87

Find this article


#33

Deger, S
High dose rate brachytherapy of localized prostate cancer

European Urology 2002;41(4):420-426

Find this article


#34

Deger, S
High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer

Eur Urol 2005;47(4):441-48

Find this article


#35

Demanes, D J
Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation

Am J. Clinical Oncology 2009;32(4):342-347

Find this article


#36

Feng, F
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer

IJROBP 2013;86(1):64-71

Find this article


#37

Feng, F
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer

IJROBP 2013;86(1):64-71

Find this article


#38

Freedland, S
Radical Prostatectomy for clinical stage T3a disease

Cancer 2007;109(7):1273-78

Find this article


#39

Fujimura, T
Robot-assisted radical prostectomy significntly reduced biochemical recurrence compared to retro pubic radical prostatectomy.

BMC Cancer 2017;17(1):454

Find this article


#40

Fujimura, T
Robot-assisted radical prostectomy significntly reduced biochemical recurrence compared to retro pubic radical prostatectomy.

BMC Cancer 2017;17(1):454

Find this article


#41

Furukawa, J
Oncologic outcome of radical prostatectomy as monotherpay for men with high-risk prostate cancer.

Curr Urol 2016;9(2):67-72

Find this article


#42

Galalae, R
The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer- a benchmark for high-tech external beam radiotherapy alone?

Brachytherapy 2014;13(2):117-22

Find this article


#43

Galalae, R
Long-term outcome by risk factors using conformal high dose brachy boost with or without Neoadjuvant androgen suppression for localized prostate cancer

IJROBP 2004;58(4):1048-1055

Find this article


#44

Galalae, R
Hypofractionated Conformal HDR Brachytherapy in Hormone Naïve Men with Localized Prostate Cancer

Strahlentherapie und Onkologie 2006;181():135-141

Find this article


#45

Ganzer, R
Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer.

BJU Int 2013;112(3):322-9

Find this article


#46

Guarneri, A
Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PDSA levels: a single institution analysis

J Ca Res Clin Oncol 2013;139(7):1141-7

Find this article


#47

Guo, Z
Oncological outcomes of cryotherapy as primary treatment in T3 prostate cancer: experience of a single centre.

BJU Int 2015;116(1):79-84

Find this article


#48

Heemsbergen, W
Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local biochemical, clinical failure, and survival.

Radiother Oncol 2014;110(1):104-9

Find this article


#49

Hinnen, K
Long-Term Biochemical and Survival Outcome of 921 Patients Treated with I125 Permanent Prostate Brachytherapy

IJROBP 2010;76(5):1433-1438

Find this article


#50

Hou, WH
(High-risk)Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation.

Asian J Androl 2016;epub 29():

Find this article


#51

Hou, WH
(Very High-risk)Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation.

Asian J Androl 2016;epub 29():

Find this article


#52

Hsu, C
Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen-deprivation therapy

BJU Int'l 2006;99():311-314

Find this article


#53

Incrocci, L
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Lancet Oncol 2016;17(8):1061-9

Find this article


#54

Ishiyama, H
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up

J Radiat Res. 2014;55(3):509-17

Find this article


#55

Izard, M
Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones

Brachytherapy 2013;12(6):608-14

Find this article


#56

Jolnerovski, M
Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six-year outcomes and predictors of late toxicity.

Radiat Oncol 2017;12(1):99

Find this article


#57

Joseph, N
A combined single high-dose rate brachytherapy boost with fractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.

Radiother Oncol 2016;121(3):299-303

Find this article


#58

Katz, A
Stereotactic body radiotherapy with of without EBRT as treatment for organ confined high-risk prostate cancer: a six year study

Radiation Oncol 2014;9():10 pgs.

Find this article


#59

Kaushik, D
Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer.

Int Braz J Urol 2016;42(6):1091-98

Find this article


#60

Khor, R
Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer

IJROBP 2013;85(3):1679-85

Find this article


#61

Khor, R
Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer

IJROBP 2013;85(3):1679-85

Find this article


#62

Kittel, J
Long-term efficacy and toxicity of low-dose-rate 125-I prostate brachytherapy as monotherapy in low-, intermediate- and high-risk prostate cancer

IJROBP 2015;92(4):884-93

Find this article


#63

Kliment, J Jr.
The long-term outcomes of radical prostatectomy for very high-risk prostate cancer pT3b-T4 NO-1 on definitive histopathology.

Cent European J Urol 2017;70(1):13-19

Find this article


#64

Kollimeier, M
Biochemical outcome after prostate brachytherapy w/5yr minimal f/up: importance of pt selection..

IJROBP 2003;57(3):645-653

Find this article


#65

Kuban, D
Long-Term Multi-Institutional Analysis of Stage T1-T2 Prostate Cancer Treated with Radiotherapy in the PSA Era

IJROBP 2003;57(4):915-928

Find this article


#66

Kuban, D
Long term results of the MD Anderson randomized dose escalation trial for prostate cancer

IJROBP 2008;70(1):67-74

Find this article


#67

Kuban, D
Long-Term Failure Patterson and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?

IJROBP 2011;79(5):1310-17

Find this article


#68

Kulkarni, J.N.
Outcome of radical prostatectomy as primary treatment for high-risk prostate cancer patients.

Indian J Cancer 2015;52(4):646-52

Find this article


#69

Kupelian, P
Improved Biochemical Relapse-Free Survival With Increased Radiation Doses in Patients With Locaized Prostate Cancer: The Combined Experience of Nine Institutions in 1994 and 1995

IJROBP 2005;61(2):415-419

Find this article


#70

Lau, W
Radical Prostatectomy for Pathological Gleason 8 or Greater Prostate Cancer: Influence of Concomitant Pathological Veriables

J Urology 2002;167():117-22

Find this article


#71

Liss, A.
Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: the impact of Gleason pattern 5

Brachytherapy 2015;14(4):502-10

Find this article


#72

Loeb, S
Intermediate term potency, continence & survival outcomes of radical prostatectomy for clinically high risk or locally advanced prostate ca

Urology 2007;69(6):1170-1175

Find this article


#73

Magheli, A
Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy

J Urology 2007;178():1311-1315

Find this article


#74

Marshall, R
Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center

Urol Oncol 2013;32(1):38e1-7

Find this article


#75

Mearini, L
Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT2-pT3a N0R0) and outcomes.

Urologia 2014;81(2):125-32

Find this article


#76

Menon, M
Biochemical Recurrence Following Robot-assisted radical prostatectomy: analysis of 1384 patients with a median 5-year follow-up

Eur. Urol. 2010;58():838-46

Find this article


#77

Merrick, G
Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy

BJU Int. 2011;107(2):226-232

Find this article


#78

Merrick, G
Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy

BJU Int. 2011;107(2):226-232

Find this article


#79

Merrick, G
Prognostic Significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy

J. Urology 2005;66(5):1048-1053

Find this article


#80

Merrick, G
Androgen deprivation therapy dose not impact cause-specific or overall survival after permanent prostate brachytherapy.

IJROBP 2006;65(3):669-677

Find this article


#81

Merrick, G
Androgen deprivation therapy dose not impact cause specific overall survival after permanent prostate brachytherapy

IJROBP 2006;65(3):669-677

Find this article


#82

Merrick, G
Impact of Supplemental External Beam Radiotherapy and/or Androgen Deprivation Therapy on Biochemical Outcome After Permanent Prostate Brachytherapy

IJROBP 2005;61(1):32-43

Find this article


#83

Merrick, G
Impact of Supplemental External Beam Radiotherapy and/or Androgen Deprivation Therapy on Biochemical Outcome After Permanent Prostate Brachytherapy

IJROBP 2005;61(1):32-43

Find this article


#84

Mian, B
Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone

J Urology 2002;167():1675-1680

Find this article


#85

Morris, L
Does prostate-specifc antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?

Brachytherapy 2015;14():322-28

Find this article


#86

Morris, WJ
Androgen Suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.

IJROBP 2017;98(2):275-85

Find this article


#87

Morris, WJ
Androgen Suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.

IJROBP 2017;98(2):275-85

Find this article


#88

Moschini, M
Long-term untility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.

BJU Int. 2017;120(1):69-75

Find this article


#89

Moschini, M
Long-term untility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy.

BJU Int. 2017;120(1):69-75

Find this article


#90

Moyad, M
STATINS, ESPECIALLY ATORVASTATIN, MAY FAVORABLY INFLUENCE CLINICAL PRESENTATION AND BIOCHEMICAL PROGRESSION-FREE SURVIVAL AFTER BRACHYTHERAPY FOR CLINICALLY LOCALIZED PROSTATE CANCER

Urology 2005;66(6):1150-1154

Find this article


#91

Mullins, JK
The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary.

J Urol 2012;188(6):2205-10

Find this article


#92

Nguyen, Q
Long-term outcomes for men with high-risk prostate cancer treated definitively with external- beam radiotherapy with or without androgen deprivation

Cancer 2013;119(18):3265-71

Find this article


#93

Nguyen, Q
Long-term outcomes for men with high-risk prostate cancer treated definitively with external- beam radiotherapy with or without androgen deprivation

Cancer 2013;119(18):3265-71

Find this article


#94

Ohashi, T
Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer

Radiation Oncol 2014;9():13

Find this article


#95

Okamoto, K
High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer.

J Contemp Brachyther 2017;9(1):1-6

Find this article


#96

Olarte, A
Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high-risk prostate cancer.

Brachytherapy 2016;15(2):127-35

Find this article


#97

Pellizzon, A
The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition

Int'l J. Medical Sciences 2008;5(3):113-120

Find this article


#98

Pervez, N
Late toxicity and outcomes in High-risk prostate cancer patients treated with hypofractionated IMRT and Long-term androgen suppression treatment

Am J. Clinical Oncology 2017;40(2):200-206

Find this article


#99

Pierorazio, PM
Long-term survival after radical prstatectomy for men with high Gleason sum in pathologic specimen

Urology 2010;76(3):715-21

Find this article


#100

Pierorazio, PM
Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer

BJU Int 2012;109(7):988-93

Find this article


#101

Ploussard, G
Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification

Urology 2011;78(3):607-13

Find this article


#102

Pollack, A
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer

J Clin Oncol 2013;31(31):3860-68

Find this article


#103

Potters, l
12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients With Clinically Localized Prostate Cancer

J. Urology 2005;173():1562-1566

Find this article


#104

Prada, P*
Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

Radiation Oncol 2012;7():31-39

Find this article


#105

Prada, P*
Long-term biochemical results after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy for high risk prostate cancer

Radiation Oncol 2012;7():31-39

Find this article


#106

Raziee, H
Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy.

Radiother & Oncol 2017;123(3):459-65

Find this article


#107

Roehl, K
Cancer Progression and Survival Rates Following Anatomical Radical Retropubic Prostatectomy in 3478 Consecutive Patients: Long-Term Results

J. Urology 2004;172():910-914

Find this article


#108

Rosenthal, S.
A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: final results of radiation therapy oncology group phase 3 randomized trial NRG oncology RTOG 9902

IJROBP 2015;93(2):294-302

Find this article


#109

Rubio-Briones, J
Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy

Actas Urologicas Espanolas 2010;34(10):610-617

Find this article


#110

Sabolch, A
Gleason Pattern 5 is the Greatest Risk Factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation

IJROBP 2011;81(4):e351-60

Find this article


#111

Savdie, R
High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse

BJU Int 2012;110(4):71-76

Find this article


#112

Savdie, R
High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse

BJU Int 2012;110(4):71-76

Find this article


#113

Shilkrut, M
(EBRT)The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Cancer 2013;119(3):681-90

Find this article


#114

Shilkrut, M
(EBRT & Seeds)The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Cancer 2013;119(3):681-90

Find this article


#115

Shilkrut, M
Treatment outcomes in very high-risk prostate cancer treated by dose-escalation and combined-modality radiation therapy

Am J. Clinical Oncology 2016;39(2):181-8

Find this article


#116

Shilkrut, M
Treatment outcomes in very high-risk prostate cancer treated by dose-escalation and combined-modality radiation therapy

Am J. Clinical Oncology 2016;39(2):181-8

Find this article


#117

Soares, R
Minimum 5-year follow-up of 1138 consecutive laparoscopic radical prostatectomies.

BJU Int. 2015;115():546-53

Find this article


#118

Sooriakumaran, P
Biochemical Recurrence After Robot-assisted Radical Prostatectomy in a European Single-centre Cohort with a Minimum Follow-up Time of 5 Years

Eur Urol 2012;62(5):768-74

Find this article


#119

Spahn, M
Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20ng/ml: a European multi-institutional study of 712 patients

Eur Urol 2010;58():pg 1-7

Find this article


#120

Spratt, DE
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer

IJROBP 2013;85(3):686-92

Find this article


#121

Stenmark, M
Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease

IJROBP 2011;81(4):e335-44

Find this article


#122

Stock, R
Outcomes for Patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy

BJU international 2009;104(11):1631-1636

Find this article


#123

Stokes, S
Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation

IJROBP 2000;47(1):129-136

Find this article


#124

Stokes, S
Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation

IJROBP 2000;47(1):129-136

Find this article


#125

Stone, Nelson
Local control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes

IJROBP 2010;76(2):355-360

Find this article


#126

Sundi, D
Very-high-risk localized prostate cancer: definition and outcomes.

Prostate Ca Prostatic Dis 2014;17(1):57-63

Find this article


#127

Sundi, D
Very-high-risk localized prostate cancer: definition and outcomes.

Prostate Ca Prostatic Dis 2014;17(1):57-63

Find this article


#128

Surapaneni, A
Radiation therapy for clinically localized prostate cancer: Long-term results of 469 patients from a single institution in the era of dose escalation.

J Ca Res Ther 2014;10(4):951-56

Find this article


#129

Sylvester, J
15 yr biochemical relapse free survival after external beam radiation & brachytherapy for localized prostate ca: the Seattle Exp

IJROBP 2007;67(1):57-64

Find this article


#130

Sylvester, J
Ten yr biochemical relapse free survival after external beam radiation & brachytherapy for localized prostate ca: the Seattle Exp

IJROBP 2003;57(4):944-952

Find this article


#131

Taira, A
Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy

Brachytherapy 2013;12(5):408-14

Find this article


#132

Taira, A
Long-term outcomes for clinically localized Prostate Cancer Treated with permenent interstitial brachytherapy

IJROBP 2011;79(5):1336-42

Find this article


#133

Tamada, S.
Comparative effetivness of radical prostatectomy and curative radiotherapy in localized prostate cancer: long-term follow-up.

J Radiat Res. 2016;epub Dec 23():

Find this article


#134

Tendulkar, R
Redefining high-risk Prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy

IJROBP 2012;82(4):1397-1404

Find this article


#135

Thames, H
Increasing External Beam Dose for T1-T2 Prostate Cancer: Effect on Risk Groups

Int. J. Rad Onc/Bio 2006;65(4):975-981

Find this article


#136

Thomson, D
Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity

Prostate Ca 2012;Epub ahead of print- June 20():

Find this article


#137

Thüroff, S
Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years

J Urol 2013;190(2):702-10

Find this article


#138

Tomita, N
(High)High-dose rate radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5 year outcomes

J Cancer Res Clin Oncol 2016;142(7):1609-19

Find this article


#139

Tomita, N
(Very High)High-dose rate radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5 year outcomes

J Cancer Res Clin Oncol 2016;142(7):1609-19

Find this article


#140

Tsumura, H
Prostate-specific-antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer

J Contemp Brachytherapy 2016;8(2):95-103

Find this article


#141

Uchida
(Group #1)Improved Outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer.

J Urol 2015;193(1):103-10

Find this article


#142

Uchida
(Group #2)Improved Outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer.

J Urol 2015;193(1):103-10

Find this article


#143

Van Hemelryk
The outcome for patients with pathologic node-positive prostate cancer treated with intensity modulated radiation therapy and androgen deprivation therapy: a case-matched analysis of pN1 and pN0 patients.

IJROBP 2016;96(2):323-32

Find this article


#144

Vargas, C
Long-term outcomes and prognostic factors in patients treated with intraoperatively planned prostate brachytherapy

Brachytherapy 2013;12(2):120-5

Find this article


#145

Vigneault, E
High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes.

Radiother Oncol 2017;124(1):49-55

Find this article


#146

Vora, S
Nine-year outcome and toxicity in patients treated with IMRT for localized prostate cancer

J Urol 2013;In Press(02/06/2013 00:00:00):

Find this article


#147

Ward, J
Radical Prostatectomy for Clin Adv Prostate Cancer Since the Advent of PSA Testing

BJU, Int. 2005;95(6):751-756

Find this article


#148

Weller, M
Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?

Clin Genitourin Ca 2014;epub Dec 31():

Find this article


#149

Yamamoto, S
Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy

Jpn J Clin Oncol 2012;42(6):541-47

Find this article


#150

Yaxley, JW
Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years.

BJU Int 2016;epub Sept 15():

Find this article


#151

Yorozu, A
Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as predicted in Japan: Outcomes of 1300 patients

Brachytherapy 2015;14(2):111-17

Find this article


#152

Yoshioka, Y
Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions

IJROBP 2011;80(2):469-475

Find this article


#153

Yoshioka, Y
High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up.

IJROBP 2016;94(4):675-82

Find this article


#154

Yoshioka, Y
Nationwide, multicenter, retrospecitve study on high-dose-rate brachytherapy as monotherapy for prostate cancer.

IJROBP 2017;97(5):952-61

Find this article


#155

Zapatero, A
(Short ADT)High-dose radiotherapy woth short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial

The Lancet 2015;16(3):320-27

Find this article


#156

Zapatero, A
(Long ADT)High-dose radiotherapy woth short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial

The Lancet 2015;16(3):320-27

Find this article


#157

Zelefsky, M
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation

IJROBP 2007;67(2):327-333

Find this article


#158

Zelefsky, M
Long term outcome following 3-D conformal intensity modulated ext-beam radiotherapy for clinical stage T3 prostate cancer

European Urology 2008;53(6):1172-1179

Find this article


#159

Zelefsky, M
(81 Gy) Long Term Outcome of High Dose Intensity Modulated Radiation Therapy for Patients With Clinically Localized Prostate Cancer

J. Urology 2006;176():1415-1419

Find this article


#160

Zelefsky,M
(81 Gy) High Dose Radiation Delivered by Intensity Modulated Conformal Radiotherapy Improves the Outcome of Localized Prostate Cancer

J. Urology 2001;166():876-881

Find this article


#161

Zelefsky,M
(75 Gy) High Dose Radiation Delivered by Intensity Modulated Conformal Radiotherapy Improves the Outcome of Localized Prostate Cancer

J. Urology 2001;166():876-881

Find this article


#162

Zelefsky, M
(81 Gy) Long Term outcome of Conformal RT for Pca:

IJROBP 2008;71(4):1028-1033

Find this article


#163

Zelefsky, M
(86 Gy) Long Term outcome of Conformal RT for Pca:

IJROBP 2008;71(4):1028-1033

Find this article